BSTC News and Press, BioSpecifics Technologies Corp From 08/19/19

Read more ...

BioSpecifics Tech (NASDAQ: BSTC ): Q2 GAAP EPS of $0.87. Revenue of $8.85M (+12.7% Y/Y) misses by $0.13M . Press Release More news on: BioSpecifics Technologies Corp., Earnings news and commentary, Healthcare stocks news,

Editor's note: Seeking Alpha is proud to welcome John Hamblin as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Biospecifics is a ...

LYNBROOK, N.Y. , May 23, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX®&#x...

BioSpecifics Tech (NASDAQ: BSTC ): Q1 GAAP EPS of $0.60 misses by $0.02 . More news on: BioSpecifics Technologies Corp., Earnings news and commentary, Healthcare stocks news, Read more ...

In this article, I’ll present a way to invest on a drug that seems to have lots of potential, but has already lost patent protection. I’ll also present a way to more generically invest in a strategy that allows taking advantage of other similar situations. The Drug - Pentoxi...

BioSpecifics Tech (NASDAQ: BSTC ): Q4 GAAP EPS of $0.84 beats by $0.02 . Revenue of $9.85M (+47.0% Y/Y) misses by $0.04M . Press Release More news on: BioSpecifics Technologies Corp., Earnings news and commentary, Healthcare stocks news,

LYNBROOK, N.Y. , March 18, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. ...

At the end of the day, a stock is simply a share in the ownership of a business. Stock prices can fluctuate due to a multiplicity of factors in the short term, but over the long term, the stock price and the value of the business tend to move in the same direction. The more profitable the b...

NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC (NASDAQ:AMRN), Retrophin, Inc. (NASDAQ:RTRX), Sunr...